CPT code 0257U is a Proprietary Laboratory Analyses (PLA) code that identifies a single, manufacturer‑ or lab‑specific test: Very–Long Chain Acyl–CoA Dehydrogenase (VLCAD) Enzyme Activity measured in leukocytes from a blood specimen using tandem mass spectrometry (MS/MS). The assay supports diagnosis and management of VLCAD deficiency, a potentially life‑threatening disorder of fatty‑acid oxidation, making the code important for rare disease detection and targeted treatment planning nationwide. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, typical sites of service, common billing modifiers, and which payers are addressed. The publication also highlights what to expect in payer coverage patterns for proprietary laboratory assays, benchmark considerations for specialized enzymatic testing, and relevant clinical context for VLCAD deficiency. Data not available in the input for specific payer coverage policies, associated taxonomies, and ICD‑10 diagnoses are noted as unavailable. This summary is intended for national audiences involved in clinical laboratory operations, medical billing, and health policy related to rare metabolic disease testing.